Default company panoramic image

Biosortia Pharamaceuticals

Biosortia Pharmaceuticals, Obtaining the unobtainable; medicine from nature to improve life

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Dublin, OH, USA
  • Currency USD
  • Website

Company Summary

Biosortia Pharmaceuticals, obtaining the unobtainable; medicine from nature to improve life. Biosortia has opened the door to a new frontier of fascinating natural products and potential drug candidates by overcoming the challenges of accessing novel high quality bioactive compounds from uncultuable aquatic microorganisms.


  • Default avatar
    Kurt D. Dieck
    President and CEO

    Kurt spent nearly 30 yrs in healthcare, including 18 yrs at Arthur Andersen where he was a global equity partner. In 2002, Kurt joined Cardinal Health, a Fortune 20 public company as a Sr. Exec., where over his tenure he had responsibilities for Strategy, Bus. Dev. & Execution for the $100B pharmaceutical distribution segment. He worked with a broad spectrum of partners, including brand pharmaceutical manufacturers, throughout the supply chain.

  • Default avatar
    Guy T. Carter, Ph.D.
    Chief Scientific Officer

    Guy has 30 years of experience working in Pharmaceutical R&D, primarily in the discovery and development of microbial products. In the course of his career in the pharmaceutical industry he worked as a natural products discovery scientist and advanced through levels of scientific management to the overall leadership of natural products drug discovery at Wyeth Research (later acquired by Pfizer), as head of the Chemical Technologies Department.

  • Default avatar
    Ross O. Youngs
    Founder and Chairman

    Ross has over 30 years inventing products, technologies and processes for a variety of industries. Ross holds over 75 patents worldwide. Recent major innovations have included R&D 100 Award for collaboration on biopolymer technologies. In 2009, Algeaventure Systems (parent company of Biosortia) was awarded a $6M ARPA-E (US DOE, R&D) grant for algal harvesting technology which helped lead to the development of Biosortia’s drug discovery platform.

  • Default avatar
    Peter Hug, Ph.D.
    Senior Scientist

    Peter contributes to Biotechnology development at Biosortia. Dr. Hug has a PhD in Molecular Genetics, Biochemistry and Microbiology. He has conducted research at the National Cancer Institute in Bethesda, Md. and Master Chemical Corporation. Dr. Hug earned his Ph.D. in Molecular Genetics, Biochemistry, and Microbiology from the University of Cincinnati.

  • Default avatar
    Peter Moeller, Ph.D.

    NOAA Research Scientist leads the Toxins Natural Products Program at Hollings Marine Laboratory and is a faculty member at Medical University of South Carolina. Dr. Moeller has over 30 years of experience specifically in the aquatic environment. He has been involved with AVS since 2010. His early research of our biomass showed more bioactivity then he had seen in his 30 years. Peter provides daily counsel to our research team that is imbedded